» Articles » PMID: 29506489

AKT1 Restricts the Invasive Capacity of Head and Neck Carcinoma Cells Harboring a Constitutively Active PI3 Kinase Activity

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2018 Mar 7
PMID 29506489
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In mammals, the AKT/PKB protein kinase family comprises three members (AKT1-3). PI3-Kinase (PI3K), a key oncogene involved in a wide variety of cancers, drives AKT activity. Constitutive activation of the PI3K/AKT pathway has been associated with tumorigenic properties including uncontrolled cell proliferation and survival, angiogenesis, promotion of cellular motility, invasiveness and metastasis. However, AKT1 activity has also been recently shown to repress the invasive properties of breast cancer cells in specific contexts.

Methods: This study used both pharmacological and shRNA approaches to inhibit AKT function, microscopy to characterize the cellular morphology, 3D spheroid models to assess migratory and invasive cellular capacities and a phenotypic screening approach based on electrical properties of the cells.

Results: Here we demonstrate that the alternative action of AKT1 on invasive properties of breast cancers can be extended to head and neck carcinomas, which exhibit constitutive activation of the PI3K/AKT pathway. Indeed, inhibition of AKT1 function by shRNA or a specific pharmacological inhibitor resulted in cellular spreading and an invasive phenotype. A phenotypic screening approach based on cellular electrical properties corroborated microscopic observations and provides a foundation for future high-throughput screening studies. This technique further showed that the inhibition of AKT1 signaling is phenocopied by blocking the mTORC1 pathway with rapamycin.

Conclusion: Our study suggests that the repressive action of PI3K/AKT1 on cellular invasive properties may be a mechanism common to several cancers. Current and future studies involving AKT inhibitors must therefore consider this property to prevent metastases and consequently to improve survival.

Citing Articles

Identification of Molecular Targets and Potential Mechanisms of Yinchen Wuling San Against Head and Neck Squamous Cell Carcinoma by Network Pharmacology and Molecular Docking.

Zhang B, Liu G, Wang X, Hu X Front Genet. 2022; 13:914646.

PMID: 35873484 PMC: 9306494. DOI: 10.3389/fgene.2022.914646.


The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An Study on a Novel Combination Strategy.

Zaryouh H, De Pauw I, Baysal H, Pauwels P, Peeters M, Vermorken J Front Oncol. 2021; 11:697967.

PMID: 34568028 PMC: 8462273. DOI: 10.3389/fonc.2021.697967.


Downregulation of long non-coding RNA B-Raf proto-oncogene-activated non-coding RNA reverses cisplatin resistance in laryngeal squamous cell carcinoma.

Han W, Niu L, Wang L, Liu J, Li H Arch Med Sci. 2021; 17(5):1164-1174.

PMID: 34522245 PMC: 8425235. DOI: 10.5114/aoms.2019.91352.


Targeting Akt in cancer for precision therapy.

Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y J Hematol Oncol. 2021; 14(1):128.

PMID: 34419139 PMC: 8379749. DOI: 10.1186/s13045-021-01137-8.


Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.

Alwhaibi A, Verma A, Artham S, Adil M, Somanath P Biochem Pharmacol. 2019; 168:1-13.

PMID: 31202735 PMC: 6733630. DOI: 10.1016/j.bcp.2019.06.010.


References
1.
Maroulakou I, Oemler W, Naber S, Tsichlis P . Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007; 67(1):167-77. DOI: 10.1158/0008-5472.CAN-06-3782. View

2.
Hutchinson J, Jin J, Cardiff R, Woodgett J, Muller W . Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004; 64(9):3171-8. DOI: 10.1158/0008-5472.can-03-3465. View

3.
Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A . Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015; 171(4):463-70. PMC: 5278973. DOI: 10.1111/bjh.13603. View

4.
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J . A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014; 111(10):1932-44. PMC: 4229637. DOI: 10.1038/bjc.2014.497. View

5.
Li C, Xia W, Lim S, Hsu J, Huo L, Wu Y . AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016; 76(6):1451-62. PMC: 4794388. DOI: 10.1158/0008-5472.CAN-15-1941. View